双周S-1、亚叶酸钙和吉西他滨治疗老年局部晚期或转移性胰腺腺癌的前瞻性II期研究:台湾肿瘤合作组织T1217研究
这项前瞻性II期研究纳入49例年龄≥70岁的初治局部晚期或转移性胰腺腺癌患者,采用双周GSL方案(吉西他滨800 mg/m2、S-1和亚叶酸钙)。主要终点无进展生存期达到6.6个月(95%CI 5.4-9.2),总生存期12.5个月(95%CI 8.9-14.7),研究达到主要终点,支持进一步研究GSL在亚洲老年患者中的价值。
要点
- GSL方案治疗老年晚期胰腺腺癌的中位无进展生存期为6.6个月(95%CI 5.4-9.2),达到主要终点。
- 中位总生存期为12.5个月(95%CI 8.9-14.7),客观缓解率26.5%,疾病控制率75.5%。
- 最常见3-4级治疗相关毒性为贫血(20.4%)、中性粒细胞减少(18.4%)和黏膜炎(12.2%)。
核心结论
- 研究达到主要终点,支持进一步研究GSL方案在亚洲老年晚期胰腺腺癌患者中的价值。
研究设计与样本
- 前瞻性II期研究,纳入49例年龄≥70岁、ECOG体能评分≤2的初治局部晚期或转移性胰腺腺癌患者。
- 治疗方案为双周GSL方案:第1天吉西他滨800 mg/m2以10 mg/m2/min输注,第1-7天每日两次口服S-1(40-60 mg)和亚叶酸钙(30 mg)。
- 主要终点为无进展生存期,预设目标P1为5.0个月。
主要发现
- 中位年龄76岁,ECOG体能评分≥1者占59.2%,转移性疾病占65.3%,Vulnerable Elders Survey-13评分≥3者占71.4%,Geriatric 8评分≤14者占93.9%。
- 中位治疗11个周期后,客观缓解率为26.5%,疾病控制率为75.5%。
- 中位无进展生存期为6.6个月(95%CI 5.4-9.2),中位总生存期为12.5个月(95%CI 8.9-14.7)。
- 最常见的3-4级治疗相关毒性为贫血(20.4%)、中性粒细胞减少(18.4%)和黏膜炎(12.2%)。
- GSL治疗期间患者情绪功能和整体健康状况评分改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elderly patients with advanced pancreatic adenocarcinoma (APC) are conceived to be frailer and susceptible to treatment toxicity that has led to disparity in lower likelihood of receiving chemotherapy and survival. Optimal chemotherapy is an unmet medical need for elderly patients with APC. PATIENTS AND METHODS: Patients with chemo-naive APC, age ≥70 years, and Eastern Cooperative Oncology Group (ECOG) performance score ≤2 were eligible. The treatment was consisted of biweekly gemcitabine 800 mg/m2, 10 mg/m2/min infusion on day 1 plus oral S-1 and leucovorin (40-60 and 30 mg, respectively) twice daily on days 1-7, the GSL regimen. The primary end-point was progression-free survival with an interested P1 of 5.0 months. RESULTS: Of the 49 enrolled patients, the median age was 76 years, ECOG performance score ≥1 in 59.2%, metastatic diseases in 65.3%, Vulnerable Elders Survey-13 score ≥3 in 71.4%, and Geriatric 8 score ≤14 in 93.9%. After a median 11 cycles of treatment, the overall response rate and disease control rate were 26.5% and 75.5%, respectively. The median progression-free and overall survivals were 6.6 months (95% confidence interval [CI], 5.4-9.2) and 12.5 months (95% CI, 8.9-14.7), respectively. The most common grade 3-4 treatment-related toxicities were anaemia (20.4%), neutropenia (18.4%), and mucositis (12.2%). Patients had improved emotional function and global health status scores during the GSL treatment. CONCLUSION: The study met its primary end-point, which supports further investigation on the merit of GSL in Asian elderly APC patients.
引用
- Bai LY, Li CP, Shan YS, et al. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - The Taiwan Cooperative Oncology Group T1217 study. Eur J Cancer. 2022. PMID: 35932625. doi:10.1016/j.ejca.2022.06.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。